Piasky-Crovalimab-Akkz
Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.
Datroway-Datopotamab Deruxtecan-Dlnk
Datroway is an antibody-drug conjugate for adults with advanced non-small cell lung cancer that has an EGFR mutation and progressed after standard treatment. It delivers targeted chemotherapy directly to cancer cells to control tumor growth.
Bizengri-Zenocutuzumab-Zbco
Bizengri is an IV antibody therapy for adults with advanced non-small cell lung cancer or pancreatic cancer driven by NRG1 gene fusions, used after standard treatments fail. It blocks the fusion protein’s signaling to help shrink tumors and control disease progression
Vyloy-Zolbetuximab-Clzb
Vyloy is used with fluoropyrimidine and platinum-based chemotherapy as the first-line treatment for HER2-negative gastric or gastroesophageal junction cancer, which cannot be removed by surgery or has spread and tests positive for claudin (CLDN)18.2.
Ziihera-Zanidatamab-Hrii
Ziihera is the first and only approved bispecific antibody drug. It treats unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. This drug is given to patients who have already received the other chemotherapeutic treatment.
Unloxcyt-Cosibelimab-Ipdl
Unloxcyt is an IV anti–PD-L1 antibody for adults with advanced or metastatic cutaneous squamous cell carcinoma who are not surgical or radiation candidates. It helps the immune system fight cancer by blocking PD-L1, with a documented response in nearly half of patients.
Lynozyfic-Linvoseltamab-Gcpt
Lynozyfic is a monotherapy for adults with relapsed and refractory multiple myeloma after ≥3 prior therapies. This bispecific T-cell engager bridges CD3 on T-cells with BCMA protein on myeloma cells to activate cancer-cell killing. FDA and EMA approved for heavily pretreated patients who have exhausted standard treatment options.
Andembry-Garadacimab-Gxii
Andembry is a preventive therapy for hereditary angioedema (HAE) in adults and adolescents 12+ years. This selective Factor XIIa inhibitor targets the top of the inflammatory cascade with once-monthly dosing. FDA-approved in June 2025, offering the first monthly prophylactic HAE treatment targeting Factor XIIa.
Enflonsia-Clesrovimab-Cfor
ENFLONSIA is a long-acting, preventive monoclonal antibody developed to protect infants against a broad range of respiratory syncytial virus (RSV) disease severity. This includes severe cases that may lead to hospitalization. It is the first and only RSV preventive option that offers a weight-independent, single-dose administration, simplifying protection across all infants regardless of size or […]
Emrelis-Telisotuzumab Vedotin-Tllv
Emrelis is an antibody‑drug conjugate for adults with locally advanced or metastatic non-squamous non-small cell lung cancer overexpressing c‑Met after prior therapy. It delivers targeted chemotherapy directly to cancer cells to inhibit tumor progression.
